During the past decade, Brigham and Women's Hospital , Department of Neurology conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Brigham and Women's Hospital , Department of Neurology" #1 sponsor was "Biogen" with 2 trials, followed by "Brigham and Women's Hospital" with 1 trials sponsored, "Columbia University" with 1 trials sponsored, "Global Blood Therapeutics" with 1 trials sponsored and "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Brigham and Women's Hospital , Department of Neurology" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Brigham and Women's Hospital , Department of Neurology" are "Alzheimer's Disease" (3 trials), "Alzheimer Disease" (1 trials), "Amyotrophic Lateral Sclerosis" (1 trials), "At Risk for Cognitive Decline" (1 trials) and "Dementia, Mild" (1 trials). Many other conditions were trialed in "Brigham and Women's Hospital , Department of Neurology" in a lesser frequency.

Most popular intervention types in "Brigham and Women's Hospital , Department of Neurology" are "Drug" (6 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Aducanumab" (1 trials), "BIIB092" (1 trials), "Bapineuzumab" (1 trials) and "Brain Health Champion" (1 trials). Other intervention names were less common.

The vast majority of trials in "Brigham and Women's Hospital , Department of Neurology" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Brigham and Women's Hospital , Department of Neurology". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 2 completed trials in Brigham and Women's Hospital , Department of Neurology, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Brigham and Women's Hospital , Department of Neurology, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".